Grant of Options

RNS Number : 2656Y

ValiRx PLC

22 January 2014

 

22 January 2014

ValiRx Plc

("ValiRx" or the "Company")

Grant of options

ValiRx Plc (AIM: VAL), the AIM listed life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that on 21 January 2014 it granted 133,000,000 options over ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to certain employees and directors of the Company, as set out in the table below.

Name of director	Number of shares held	% of issued share capital	Number of existing options	Number of new options granted	Total options now held	Options held as % of issued share capital
Satu Vainikka	22,324,198	0.76%	11,000,000	24,000,000	35,000,000	1.20%
George Morris	18,535,993	0.63%	6,750,000	22,000,000	28,750,000	0.98%
Gerry Desler	11,137,953	0.38%	6,400,000	22,000,000	28,400,000	0.97%
Kevin Alexander	6,421,940	0.22%	6,400,000	20,000,000	26,400,000	0.90%
Oliver de Giorgio-Miller	2,444,411	0.08%	3,000,000	20,000,000	23,000,000	0.79%
Seppo Makinen	Nil	Nil	Nil	8,000,000	8,000,000	0.27%
Total Directors	60,864,494	2.08%	33,550,000	116,000,000	149,550,000	5.12%
Others	Nil	Nil	6,100,000	17,000,000	23,100,000	0.79%
Total	60,864,495	2.08%	46,050,000	133,000,000	172,650,000	5.91%

The new options were granted under the Company's stock option plan and have an exercise price of 0.345p pence.  The new options are exercisable from 21 January 2014 until 20 January 2024.

Following the grant of the new options, the total number of Ordinary Shares under option held by directors which could be issued is 149,550,000 Ordinary Shares, representing approximately 5.12 per cent. of the current issued share capital of the Company.

In addition, a further 17,000,000 options have been granted to others at an exercise price of 0.345 pence which are exercisable until 20 January 2024.

As at the date of this announcement the Company has a total of 179,050,000 shares under option.

The issued share capital of the Company comprises 2,921,043,420 ordinary shares of 0.1 pence each.

For more information, please contact:

Dr Satu Vainikka	ValiRx	Tel: [phone] www.ValiRx.com
Liam Murray Avi Robinson	Nominated Adviser Cairn Financial Advisers	Tel: [phone]
David Hart Mark Treharne	Broker Daniel Stewart & Company	Tel: [phone]
Tarquin Edwards	Investor Relations Peckwater PR	Tel: [phone] [e-mail]

 

END

 

 

MSCBXGDBBBDBGSD